Almirall closed 2023 with a Net Sales growth of 4%, mainly driven by its European dermatology business. Tazorac® United States Total Sales: €7.9 MM Azelex® United States Total Sales: €9.5 MM EBGLYSS® Germany* Total Sales: €1.2 MM *EBGLYSS® was launched in December 2023. ** Prometax® was acquired in September 2023. *** Physiorelax® was acquired in February 2023. Almax® Spain South Korea Ivory Coast Panama Andorra Total Sales: €36.3 MM Crestor® Spain Total Sales: €44.0 MM Sativex® franchise Germany Spain Italy Switzerland Norway Belgium Austria Denmark Portugal Sweden Luxembourg Poland Finland Ireland Iceland Total Sales: €36.4 MM Prometax® Spain** Total Sales: €3.7 MM Physiorelax® franchise Spain*** Total Sales: €3.8 MM Other strategic products Ebastel® franchise Spain Italy China Sweden Portugal Germany Utd.Arab.Emir. Finland France South Korea Pakistan Brazil Japan Qatar Ivory Coast Turkey Greece Belgium Panama Norway Denmark Kuwait Iceland Estonia Lebanon Netherlands Cyprus Bahrain Luxembourg Lithuania Kenya Andorra Total Sales: €62.9 MM Efficib®/ Tesavel® Spain Total Sales: €23.2 MM